Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Home
Member Profile
Onesmo Balemba
Personal Information
Title
Associate Professor
Expertise
Gastro-Intestinal (GI)
Institution
University of Idaho
ORCID
https://orcid.org/0000-0003-1034-2242
Newsletter?
Not signed up.
Data Summary
Type
Count
Grants/SubContracts
1
Progress Reports
1
Publications
0
Protocols
0
Committees
2
Grants/Applications
Progress Reports
Publications
Presentations
Protocols
Committees
A study to explore novel causes of diabetes neuropathy and dysmotility in the gut
Damage to enteric nervous system (ENS) causes gastrointestinal (GI) motility disorders in type two diabetes (T2D) patients and insulin resistance. It is believed that molecules derived from diet-gut microbiota-host interactions—particularly palmitate, lipopolysaccharide (LPS) and lipoteichoic acid act synergistically to damage the ENS neurons and disrupt GI movements in prediabetes and T2D patients. Still, knowledge of the role of molecules derived from diet-gut microbiota-host interactions in causing diabetic ENS neuropathy and GI dysmotility is extremely limited. We have discovered that sterile fluid (supernatants) from of distal ileum and cecum contents of diabetic and nondiabetic C57BL/6 mice restricted to high fat diet (HFD) for 8 weeks (nondiabetic female or diabetic male mice) inhibit intestinal propulsion in vitro. Furthermore, they damage nitrergic and cholinergic myenteric neurons and inhibits the excitability of smooth muscle cells. Supernants with these damaging effects are likely produced before mice develop diabetes phenotype (obesity, hyperglycemia, insulin resistance), because supernatants of 2-week HFD mice (normal glycemic) block muscle contractions. All these changes match the effects of HFD ingestion but are in sharp contrast to results obtained in using supernatants of mice fed standard chow diet (SCD). Palmitate, short chain fatty acids, glucose, LPS and lipoteichoic acid (LTA) do not mimic the antimotility effects of supernatant from HFD mice individually or when mixed together. Our results suggest that ileocecal supernatants of HFD mice contain unknown molecules—that disrupt motility by impairing ENS neurons and smooth muscle cells, before the type two diabetes. We believe that fecal supernants from prediabetes and T2D patients contain such molecules. Our objective here is to test the hypothesis that transplantation of supernatants of feces from mice restricted to HFD for 8 weeks, and prediabetes or T2D humans into healthy mice, will alter gut motility by disrupting neurotransmission in the ENS. We believe that this will confirm our ex vivo results, and the idea that unknown toxins from intestinal contents trigger GI ENS neuropathy and dysmotility before insulin resistance. In future research we will focus our efforts on studying supernatants from 1-2weeks HFD mice, chemical identification of toxins in supernatants and their mechanisms of action. Therefore, our work may have ramifications for understanding the etiology of both neuropathy and T2D, lead to new biomarkers and therapeutic targets for GI dysmotility, diabetic neuropathy and neurodegeneration.
Progress Reports
Drag a column header and drop it here to group by that column
Application
Complete Date
Report
Options
A study to explore novel causes of diabetes neuropathy and dysmotility in the gut (Balemba, Onesmo)
6/29/2023
View Progress Report Document
Annual Reports
No uploaded documents found.
Publication
Altmetrics
Submitted By
PubMed ID
Status
Options
No records to display.
No uploaded documents found.
No protocols found.
Name
Description
Steering Committee
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
Gastro-Intestinal (GI)
The DiaComp Gastro-Intestinal (GI) Committee has the principal function of furthering the mission of the consortium with regard to diabetic gastro-intestinal (GI) and liver disease
Curation Flag Information
Display Stats
New comment to be added:
Flag Active?
OrderID
Experiment
Species
Status
Measurements
Options
No records to display.
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!